BioNTech SE (22UA) — Cash Flow-to-Debt Ratio
BioNTech SE (22UA) has a Cash Flow-to-Debt Ratio of -0.18x as of March 2026, meaning its operating cash flow of €-421.00 Million could theoretically repay 0% of its total liabilities (€2.38 Billion) in one year. See BioNTech SE free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BioNTech SE Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for BioNTech SE across 9 annual periods. Also explore 22UA year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for BioNTech SE (2017–2025)
Year-by-year debt coverage analysis for BioNTech SE. For market capitalisation and broader financial context, see BioNTech SE market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.16x | €456.00 Million | €2.76 Billion | ▲ +147.7% |
| 2024 | 0.07x | €207.70 Million | €3.12 Billion | ▼ -96.6% |
| 2023 | 1.95x | €5.37 Billion | €2.76 Billion | ▼ -53.8% |
| 2022 | 4.21x | €13.58 Billion | €3.22 Billion | ▲ +1763.9% |
| 2021 | 0.23x | €889.70 Million | €3.94 Billion | ▲ +1684.8% |
| 2020 | -0.01x | €-13.50 Million | €946.77 Million | ▲ +97.8% |
| 2019 | -0.65x | €-198.50 Million | €304.15 Million | ▼ -327.8% |
| 2018 | -0.15x | €-58.88 Million | €385.99 Million | ▼ -22.7% |
| 2017 | -0.12x | €-52.56 Million | €422.92 Million | — |